Robert Driscoll
Stock Analyst at Wedbush
(2.22)
# 2,807
Out of 5,056 analysts
153
Total ratings
35.56%
Success rate
-0.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $36 → $38 | $11.08 | +242.96% | 11 | Nov 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $77 → $80 | $70.58 | +13.35% | 8 | Nov 6, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $31 → $38 | $12.01 | +216.40% | 2 | Oct 20, 2025 | |
| REPL Replimune Group | Upgrades: Outperform | $4 → $18 | $8.74 | +105.95% | 7 | Oct 20, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $13.00 | +107.69% | 1 | Jul 14, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.36 | +194.12% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $0.92 | +555.59% | 3 | May 9, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $13.78 | +23.37% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $12.99 | -7.62% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $8.57 | +273.40% | 6 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $33.71 | +54.26% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $16.04 | +74.56% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $3.97 | +303.02% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $20.19 | +48.59% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.60 | +731.67% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $8.54 | +321.55% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.19 | +824.37% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.02 | +158.96% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $8.00 | +62.50% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $29.02 | +155.00% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $4.93 | +62.27% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.11 | +530.63% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $3.66 | +118.58% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.45 | -10.11% | 4 | May 19, 2020 |
Kura Oncology
Nov 14, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $11.08
Upside: +242.96%
Revolution Medicines
Nov 6, 2025
Maintains: Outperform
Price Target: $77 → $80
Current: $70.58
Upside: +13.35%
Corbus Pharmaceuticals Holdings
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $12.01
Upside: +216.40%
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $4 → $18
Current: $8.74
Upside: +105.95%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $13.00
Upside: +107.69%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.36
Upside: +194.12%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.92
Upside: +555.59%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $13.78
Upside: +23.37%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $12.99
Upside: -7.62%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $8.57
Upside: +273.40%
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $33.71
Upside: +54.26%
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $16.04
Upside: +74.56%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $3.97
Upside: +303.02%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $20.19
Upside: +48.59%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.60
Upside: +731.67%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $8.54
Upside: +321.55%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.19
Upside: +824.37%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.02
Upside: +158.96%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $8.00
Upside: +62.50%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $29.02
Upside: +155.00%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $4.93
Upside: +62.27%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.11
Upside: +530.63%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $3.66
Upside: +118.58%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.45
Upside: -10.11%